Shares represent units of ownership within a company. Shares are also known as stocks or equities. Dividend payments are common with some companies, a method of sharing company profits with shareholders. In addition to traditional share dealing, however, traders can access derivatives: trading instruments derived from the movement of an underlying share price. Individual stock CFDs (contract for differences) fall under the umbrella of derivative products, an effective low-cost trading vehicle. While CFDs do not grant shareholder privileges, active CFD positions may receive a dividend if executed before the ex-dividend date.

What is the difference between CFD and Shares?

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company. While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

What are the most traded share CFDs?

Supply and demand are the main two pillars of share price sharping. The economic situation of countries, in addition to geopolitical risks and instability, can undoubtedly affect trade, financial flow, and consequently the share CFDs prices. In such situations the stock market price fluctuations can be excessively strong, creating opportunities for traders to generate returns investing on the foreign exchange but also excessive risks. Thus, some well-performing companies offer more opportunities to traders due to their stable, smooth, and less volatile share price movement in the markets. Some of the top traded share CFDs represent the trending industries. Technology companies such as Tesla Inc, Apple, Microsoft, and Facebook are some of the trader’s favorite shares to trade according to Investing.com. While some of the biotech representatives that have entered the top traded list of the global markets are Moderna, Pfizer, and Johnson & Johnson.

What factors should I consider when trading Share CFDs?

The main two driving forces of the forex currency market‘s volatility are supply and demand, placing the share CFDs trading amongst the most distinct volatility performers in the markets. The economic situation of countries and unions, in addition to geopolitical risks and instability, can undoubtedly affect trade, financial flow, and consequently the interest rate of currencies, economies, and companies. In such situations the stock market price fluctuations can be excessively strong, creating opportunities for traders to generate returns investing on the share CFDs. For instance, the current global pandemic situation has resulted in traders’ interest turning towards pharmaceutical and biotech companies, delivery and transportation as well as streaming and production services.

CSL Ltd (CSL) Stock Price, News & Insights

CSL Ltd (CSL) Profile

CSL (ASX: CSL) is a multinational biotechnology company established in 1916, with headquarters in Melbourne, Australia. The company began operations as Commonwealth Serum Laboratories over a century ago, and was owned by the Australian federal government until 1994 when it became publicly listed and traded on the Australian Securities Exchange (ASX).
The Australian company provides patients in more than 100 countries with advanced lifesaving medicines against rare diseases (CSL Behring), iron deficiency (CSL Vifor), and is also one of the leading influenza vaccine providers in the world (CSL Seqirus). In 2024, CSL delivered the first self-amplifying mRNA (sa-mRNA) Covid-19 vaccine for initial and booster vaccinations.

Why Trade CSL (CSL) Shares?

In February 2025, CSL published its H1 FY25 report (which ended on 31 December 2024). CSL delivered a solid H1 FY25 performance, with revenue increasing by 5% to reach US$8,483 million. The CSL Behring division led with 10% revenue growth in the first half of the fiscal year, followed by CSL Vifor, which managed to increase its individual revenue by 6%. On the contrary, CSL’s Seqirus vaccine unit saw its revenue decline by 9% for the same period, missing analysts’ expectations. CSL’s executives stated that the vaccine unit’s performance was negatively influenced by a recorded decline in Covid-19 immunisation rates in the US. However, hospitalisation rates had increased, posing a public health risk.

CSL’s total net profit surged by 6% to US$2.01 billion but still missed economists’ forecasts of US$2.09 billion. Despite market analysts raising questions about how the company could achieve its FY25 Net Profit After Tax And Amortisation (NPATA) guidance, CSL’s report suggested that full-year profit could rise between 10% and 13% on the back of CSL Behring and CSL Vifor’s efficient performances.

What Influences the Price Of CSL?

Financial Performance and Earnings Reports

The financial performance of a company can influence its share price. Companies publish their earnings reports every quarter, allowing investors and traders access to official financial updates and forward guidance. The four quarterly reports are accompanied by an annual report released at the end of each fiscal year.

An earnings report may include revenue growth, net profit, and earnings per share (EPS) figures, among other key data. The company’s share price generally increases (decreases) if earnings figures surpass (fail to meet) analysts’ expectations.

Product Pipeline and R&D Progress

Pharmaceutical companies’ growth depends on their product pipeline as well as progress on Research and Development (R&D). In September 2024, the Japanese Ministry of Health, Labour & Welfare approved CSL’s KOSTAIVE®, the first sa-MRNA Covid-19 vaccine for adults over 18 in the world. The company also launched FLUAD®, an influenza product in South Korea and Taiwan.

CSL management has vowed to keep investing in R&D and its product portfolio to enhance patient care and public health. According to a CSL report, the company invested US$1.4 billion in R&D for its three divisions and plans to continue doing so in order to strengthen its leading position in the biotechnology industry.

Competition and Market Share

CSL is one of the world's market-leading biotech companies, offering an array of drugs that help patients with haemophilia and iron deficiencies, as well as influenza-preventing vaccines. However, maintaining its position in such a competitive business environment remains challenging, especially when CSL’s main rivals are companies such as Pfizer, Roche, etc. While CSL intends to continue upgrading its R&D division, offering new solutions to patients worldwide, a major breakthrough by any of its competitors could act as a headwind to the Australian company’s plans.

External Factors: Pandemics and Geopolitical Events

The onslaught of the Covid-19 pandemic in 2020 impacted how most industries function globally. Lockdowns forced pharmaceuticals to work on creating vaccines for a virus that put most aspects of global economic activity on pause. As CSL is one of the largest vaccine-producing companies in the world, any unexpected event, such as the Covid-19 pandemic, could play a role in shaping its share price.

Another factor that could impact the company’s plan and performance is the change of guard in the White House. The new US administration plans to reevaluate the healthcare budget expenses, trying to limit the federal budget deficit. Although it would be still early to assess the situation, the appointment of certain people with anti-vaccine views to high-ranking positions within the US Department of Health and Human Services may influence CSL’s performance in the long-run.

How Can I Trade CSL (CSL) Share CFDs?

Contracts for Differences (CFDs) are trading instruments that let traders speculate on the price direction of an asset – like CSL shares in this case – without owning the asset itself. Traders can choose to go long if they forecast a rise in price, or short if they anticipate a drop. One key feature of CFDs is leverage, which allows traders to open larger positions than their initial deposit using margin.

OPEN ACCOUNT TRY DEMO

CSL Ltd (CSL) Trading - FAQs

Why should you invest in CSL?

CSL Ltd is one of the leading global biotech companies. CSL’s product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical, genetic research, and manufacturing applications. Since the beginning of 2025, CSL’s share price has lost almost 12% in value. Nevertheless, CSL leadership has vowed to continue supporting its 2,500-strong R&D department with an increased budget while expanding the geography and use of medicines for rare and specialty diseases across the globe.

What are the advantages of trading CSL Share CFDs compared to buying physical shares?

The ownership factor is the major difference between trading Share CFDs and investing in physical shares. With Share CFDs, traders trade a derivative product, speculating on its price movements without owning the underlying asset. In contrast, investing in physical shares means that investors own a part of the specific company with various types of rights depending on the company, such as voting, receiving dividends, and attending general meetings.

Another major difference would be that with trading CFDs you need a small part of the total transaction, known as margin, to open a position thanks to leverage. Leverage is generally not used when investing in physical shares, forcing investors to commit larger amounts of capital to their financial plans.

How do leverage and margin work when trading CSL Share CFDs?

When trading CSL Share CFDs, leverage and margin are two primary components that allow investors to control larger positions with less upfront capital.

Margin is the initial deposit needed to open a leveraged position. For example, if CSL is trading at US$253.60 per share, purchasing 100 shares would require an initial investment of US$25,360 (US$253,60 * 100) if traded without leverage. However, if the margin requirement for CSL Share CFDs is 20%, you can open an equivalent position with US$5,072.60 (US$25,360 * 0.2). This allows you to control the full position by only putting up a fraction of its value.

By trading on margin, you have leveraged your exposure to CSL’s share price by 5:1: you can control a US$5,000 position on CSL shares by ‘putting up’ US$1,000 capital.

What are the risks associated with trading CSL Share CFDs?

Any investment in the stock market comes with certain risks; trading CFDs on CSL shares is no exception. Geopolitical tensions or changes in government sometimes have an impact on share valuations, often leading traders to adjust their strategies. In the case of a big pharma company such as CSL, technological breakthroughs by competitors and high R&D costs could cause volatility that could jeopardise even the plans of more experienced traders.

When trading CSL Share CFDs, company news (earnings) and the broader economy are risks that traders must factor into their planning. Other key risks to consider include position sizing, as well as leverage and margin. Irrespective of the financial instrument traded, it is important to recognise that traders and investors are risk managers first and foremost.

What factors should I consider before opening a CFD position on CSL?

Before opening a CFD position on CSL, you should ensure you have the necessary knowledge to build a Trading Plan that includes the necessary risk management tools to limit your losses if markets move against your forecast. Traders should also pay attention to financial news updates as any potential development related to CSL could impact the Australian company’s share price.

Can I short CSL Shares with CFDs and how does this work?

The answer is yes, you can short CSL shares with CFDs. Sometimes, you may forecast an upcoming drop in a share’s price. Using the MetaTrader 5 (MT5) or the cTrader platform and taking advantage of the trader-friendly interface, you can build your short-selling strategy based on your forecast and make the right move when you believe the timing is right.

What trading platforms are used to trade CSL Share CFDs?

CSL Share CFDs can be traded on MT5 and cTrader. Both trading platforms provide an easy-to-use and functional interface, access to a wide range of Share CFDs, reliable and fast trade execution, as well as mobile trading features allowing you to trade on the go.

What fees and charges should I be aware of when trading CSL Share CFDs?

Swap Fees (Overnight Fees):

Long positions: -8.5%
Short positions: 2.5%

Commission Charges:

A$5 minimum charge per side
0.05% per Share per side

Note that the commission charges apply to both Standard and RAW MT5 accounts.

How can CSL’s earnings reports impact CSL Share CFD trading positions?

CSL’s Share price can fluctuate following its quarterly earnings releases, depending on whether the figures meet, fall short of, or exceed investor expectations. Earnings reports provide market analysts with a thorough view of the company’s financial data, as well as forward guidance that reflects the company’s future plans. Therefore, a positive data report may boost share prices while a negative one could drive prices lower.

Choose other instrument

Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results.

START TRADING

CSL Ltd (CSL)